Presentation

Company Profile
Gentian develops and manufactures high quality in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. Their product lines of laboratory tests for diverse diagnostic targets provide high accuracy and fast results for both human and veterinary healthcare. Gentian performs production, R&D, marketing and distribution from their headquarters in Moss, Norway and their representative offices. They serve a global market for human and veterinary medical diagnostic tests via their OEM partners and key distributors as well as directly through Gentian Diagnostics AB, their Swedish distribution subsidiary. Gentian’s reagents are developed using avian antibodies and their proprietary Nanosense technology. They can be adapted for use on all major clinical chemistry analysers. Some of the addressed therapeutic areas include inflammation, infections, kidney failures, congestive heart failures and veterinary healthcare.

Recent highlights
In Q1 2021, Gentian reported a revenue of 19.6 NOKm, which represented a 24% increase y/y when adjusted for currency. In January, the company announced that their SARS-CoV-2 antibody test was moving to the next development phase. In June, the company perform a transfer of listing from Euronext Growth to Oslo Børs stock exchange.

Outlook
In the short to medium term, the company expects that the demand for Cystatin C will increase in US and Asia as a result of the targeted commercial and marketing initiatives from both Gentian and its partners. Furthermore, the company expects to expand the fCAL® GCAL® products across customers and territories. The company targets two-digit sales growth in 2021 vs 2020.